296.2 𩺠åèç
296.2.1 é«é »èé»
296.2.1.1 Autoimmune Cardiac Manifestations
- SLE: pericarditis (#1), myocarditis, Libman-Sacks, premature CAD
- RA: pericarditis (often subclinical), CAD equivalent
- Scleroderma: PAH + myocardial fibrosis
- APS: thrombosis + valve abnormalities
- PM/DM: myocarditis
296.2.1.2 Vasculitis Cardiac
- Takayasu: aortitis + coronary ostia + AR + HTN
- GCA: aortic + thoracic aneurysm
- PAN: coronary aneurysms (HBV)
- Churg-Strauss: myocarditis + Löffler endomyocardial fibrosis (ANCA, eosinophil)
- Kawasaki: coronary aneurysms (pediatric); IVIG + ASA
296.2.1.3 Infiltrative
- AL amyloid: plasma cell; daratumumab + CyBorD (ANDROMEDA)
- ATTR-wild type: elderly HFpEF; tafamidis (ATTR-ACT)
- ATTR-hereditary: TTR mutation; tafamidis + patisiran (gene silencer)
- Sarcoid: AV block + HFrEF; CMR + PET + EMB
- Hemochromatosis: DCM; phlebotomy / chelation
- Fabry: HCM mimic + renal/neuropathy; ERT
- Glycogen storage: Pompe HCM; ERT
296.2.1.4 Endocrine
- Hyperthyroidism: AF, HF
- Hypothyroidism: bradycardia, pericardial effusion
- Acromegaly: LVH, HF
- DM: cardiomyopathy + CAD
296.2.2 ææ··æ·æ¯èŒ
| Disease | Most Common Cardiac Issue | Key Treatment |
|---|---|---|
| SLE | Pericarditis | HCQ + steroids + IS |
| Scleroderma | PAH + myocardial fibrosis | PAH-specific therapy |
| Takayasu | Aortitis + coronary ostia | Steroids + biologics |
| AL amyloid | HF + conduction | Daratumumab + CyBorD |
| ATTR-wild type | HFpEF in elderly | Tafamidis |
| Sarcoid | AV block + HFrEF | Steroids + ICD |
| Hemochromatosis | DCM + arrhythmia | Phlebotomy / chelation |
| Fabry | HCM + renal | ERT (agalsidase) |
| Syphilis tertiary | Aortitis + AR | Penicillin + surgery |
| Chagas | Apical aneurysm + DCM | Anti-T. cruzi + ICD |
| HIV | Cardiomyopathy + premature CAD | ART + statin |
296.2.3 Special Topics
296.2.3.1 Lake Louise CMR Criteria for Myocarditis
- T2 hyperintensity + LGE (modified 2018)
- Useful in any myocarditis (viral, autoimmune, ICI)